Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

NCT05891821 is registered in ClinicalTrials.gov with Immune Oncology Research Institute as lead sponsor.

NCT NCT05891821
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05891821 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)
Lead sponsor
Immune Oncology Research Institute
Phase
Phase 2
Overall status
Recruiting
Start date
September 1, 2023
Completion date
September 30, 2029
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma